Neurocrine Bio. (NBIX) ph.III CAH timelines pushed back six months - RBC

RBC Capital analyst Brian Abrahams out negative on Neurocrine Bio. (NASDAQ: NBIX), noting the timeline for primary completion for NBIX's ph.III CAH studies with crinecerfont appears to have been pushed back by six months on clinicaltrials.gov.

The analyst commented, "With the CAH data now likely close to a year away, and minor pipeline setbacks accumulating (e.g., primaries for '104 studies were not met and Ingrezza schizophrenia readout delayed to 2024), we believe this further emphasizes the need for near-term pipeline success to continue stock upside, with strong Ingrezza performance now more baked into the current stock valuation. We remain Sector Perform pending greater pipeline visibility or business development."

The firm reiterated a Sector Perform rating and $117.00 price target on NBIX.

For an analyst ratings summary and ratings history on Neurocrine Bio. click here. For more ratings news on Neurocrine Bio. click here.

Shares of Neurocrine Bio. closed at $119.48 yesterday.

You May Also Be Interested In

• Neurocrine's Ingrezza study shows quality-of-life gains in TD patients
• Neurocrine Bio. (NBIX) PT Lowered to $182 at Morgan Stanley
• Freedom Broker Double Downgrades Mosaic (MOS) to Sell